Drug
Efgartigimod
Efgartigimod: highest development phase Post-Market, developed by Argenx. 13 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efgartigimod NCT06860633 | Post-Market | Myasthenia Gravis Crisis |
| efgartigimod NCT04225156 | Phase 3 | Primary Immune Thrombocytopenia |
| Efgartigimod IV NCT06544499 | Phase 3 | Primary Immune Thrombocytopenia (ITP) |
| efgartigimod NCT04188379 | Phase 3 | Primary Immune Thrombocytopenia |
| Efgartigimod IV NCT07194850 | Phase 2/3 | Immune Thrombocytopenia (ITP) |
| Efgartigimod IV NCT04833894 | Phase 2/3 | Generalized Myasthenia Gravis |
| Efgartigimod NCT05633407 | Phase 2 | Postural Orthostatic Tachycardia Syndrome |
| efgartigimod IV NCT05810961 | Phase 2 | Membranous Nephropathy |
| Efgartigimod NCT05817669 | Phase 2 | Primary Sjögren's Syndrome |
| efgartigimod IV NCT05810948 | Phase 2 | Lupus Nephritis |
| efgartigimod IV NCT04564066 | Phase 1 | Healthy Volunteers |
| Efgartigimod IV NCT05927415 | Phase 1 | Renal Impairment |
| Efgartigimod NCT05163834 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Efgartigimod on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.